Novavax revenue plunges 76% to $56.7M as COVID vaccine sales normalize; net loss -$53.4M

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 6, 2025 · ~2 min read

Key Changes

• high

  Total revenue fell 76.3% YoY to $56.7M in Q2 2026, driven by the absence of prior-year one-time items ($603M APA terminations, $175M Sanofi BLA milestone). operating income swung from $101.1M profit to $54.9M loss.

  MD&A: Revenue & Operating Results verify on EDGAR →
• high

  Net income swung from $625.2M profit (H1 2025) to $62.9M loss (H1 2026), or -$0.32 diluted EPS. The prior-year profit was driven by APA termination proceeds and the Sanofi BLA milestone; the current period reflects normalized operations without those one-time gains.

  MD&A: Net Income verify on EDGAR →
• high

  The facility bears interest at Term SOFR plus 5.00% (8.6% as of June 30), matures March 2031, and includes a $100M minimum cash covenant.

  Notes: Credit Agreement verify on EDGAR →